Personalis, Inc. (PSNL) stock
Close on Nov 11, 2026Market cap $1.70BP/E –Yield –
Personalis, Inc. grew revenue 16.9% to $80.77M over the twelve months to Sep 30, 2026. Free cash flow was -$107.69M. At the latest close the market valued the company at $1.70B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $1.70B
- P/E ratio
- –
- Price to sales
- 21.10
- Price to book
- 8.01
- Dividend yield
- –
- Free cash flow yield
- -6.32%
Fundamentals
- Revenue
- $80.77M
- Net income
- -$119.33M
- EPS, diluted
- -$1.17
- Free cash flow
- -$107.69M
- Book value per share
- $1.98
- Diluted shares
- 107M
Trading
- Next earnings
- Feb 25, 2027 (estimated, after the close)
- Previous close
- $15.88
- Open
- $15.90
- Day's range
- $15.90 – $16.04
- Volume
- 1,139,046
- Average volume (20 days)
- 2,212,822
- Index membership
- Russell 2000 (since Jun 2025), Russell 3000 (since Aug 2025)
- Beta (5 years)
- 1.88
- 52-week range
- $4.96 – $18.89
- RSI (14 days)
- 52.1
- Volatility (1 year)
- 79.4%
- Relative volume
- 0.35×
- WACC
- 14.3%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2019, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | PSNL | S&P 500 | Difference | PSNL per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -0.2% | -2.4% | +2.2 pts | ||
| 3 months | +13.8% | -1.2% | +15.0 pts | ||
| Year to date | +100.5% | +12.3% | +88.2 pts | ||
| 1 year | +89.1% | +12.4% | +76.7 pts | ||
| 3 years | +1464.7% | +78.8% | +1385.9 pts | +150.1% | +21.4% |
| 5 years | -15.9% | +75.2% | −91.1 pts | -3.4% | +11.9% |
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Personalis filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About Personalis
Services-Medical Laboratories
Personalis, Inc. operates as a cancer genomics company focused on enabling personalized cancer therapies and providing diagnostic testing solutions. The company offers specialized laboratory testing services that support clinical diagnostics and pharmaceutical research and development, including population sequencing and enterprise sales. Its service offerings assist biopharmaceutical and clinical diagnostic partners in advancing cancer therapeutics, monitoring disease progression, and supporting clinical trials. Key customers include biopharmaceutical organizations such as Moderna, Pfizer, and Merck, along with healthcare entities like AstraZeneca and government initiatives such as the U.S. Department of Veterans Affairs' Million Veteran Program.
Company profile, executives and historyPersonalis stock: common questions
What is Personalis's stock price?
PSNL closed at $15.96 on Nov 11, 2026, up 0.50% on the day. Over the past 52 weeks it traded between $4.96 and $18.89.
What is Personalis's market cap?
Personalis was worth $1.70B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is PSNL's P/E ratio?
Personalis lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.17), so it has no meaningful P/E ratio.
How much revenue does Personalis make?
Personalis reported revenue of $80.77M for the twelve months to Sep 30, 2026, up 16.9% from a year earlier.
Does Personalis pay a dividend?
No. Personalis has not paid a cash dividend over the last twelve months.
When does Personalis report earnings next?
Personalis is expected to report Q4 FY2026 results on Feb 25, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has PSNL stock performed over the past year?
Including dividends, PSNL returned +89.1% over the past year, against +12.4% for the S&P 500.
How many PSNL shares are sold short?
7M shares were sold short at the latest FINRA report, 7.44% of the float, or 3.3 days of average trading volume.
Who are Personalis's competitors?
Companies most similar to Personalis by business, industry and size include GRAL, BDSX, MDXH, FLGT, XGN.
See a number that looks wrong?